Recursion Pharmaceuticals, Inc.
RXRX
$3.16
-$0.15-4.53%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 18.51% | -81.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 18.51% | -81.79% | |||
| Cost of Revenue | 0.72% | -8.92% | |||
| Gross Profit | 0.51% | -25.76% | |||
| SG&A Expenses | 20.07% | -17.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.68% | -11.43% | |||
| Operating Income | -5.03% | -9.97% | |||
| Income Before Tax | -7.29% | -12.96% | |||
| Income Tax Expenses | 99.98% | -23,120.00% | |||
| Earnings from Continuing Operations | -11.49% | -8.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.49% | -8.68% | |||
| EBIT | -5.03% | -9.97% | |||
| EBITDA | -7.32% | -11.77% | |||
| EPS Basic | -10.81% | -8.13% | |||
| Normalized Basic EPS | -6.66% | -4.19% | |||
| EPS Diluted | -10.81% | -8.13% | |||
| Normalized Diluted EPS | -6.66% | -4.19% | |||
| Average Basic Shares Outstanding | 0.60% | 0.49% | |||
| Average Diluted Shares Outstanding | 0.60% | 0.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||